DOI: 10.25881/BPNMSC.2020.55.86.022


Zhiburt E.B., Kuznecov S.I.

Pirogov National Medical and Surgical Center, Moscow


In 2019, the Nobel prize in medicine was awarded to three scientists who found that the response to hypoxia is mediated by specific segments of DNA located next to the erythropoietin (EPO) gene. This mechanism of oxygen perception is present in almost all tissues. A protein complex that binds to the above-mentioned DNA segment in an oxygen-dependent manner is called a hypoxia - induced factor (HIF). The discovery of prolylhydroxylases that regulate the stability of HIF-1α allowed us to find hydroxylase inhibitors to increase the level of HIF, which opened new pathways for pharmacological discoveries. In fact, a number of potential drugs are being created that increase HIF function by inhibiting prolylhydroxylase enzymes. Thus, the implementation of the discovery of the Nobel laureates in 2019 fits into the blood-saving ideology adopted at the Pirogov center.

Keywords: anemia, oxygen, erythropoietin, hypoxia- inducible factor, prolylhydroxylase, patient blood management.


1. [Internet]. The Nobel Prize. About the prize. Explore prizes and laureates [cited 2019 Dec 9]. Available from:

2. Shevchenko YuL, Danil’chenko VV, Zhiburt EB, et al. Eritropoetin v profilaktike i lechenii anemii. Voen Med Zh. 1996;317(11):45–48. (In Russ).

3. Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001–1010. doi: 10.1056/NEJMoa1813599.

4. Shevchenko YuL, Zhiburg EB, Shestakov EA. Introduction of blood-saving ideology in the practice of the Pirogov center. Bulletin of Pirogov National Medical & Surgical Center. 2008;3(1):14–21. (In Russ).

For citation

Zhiburt E.B., Kuznecov S.I. Nobel 2019 – a new alternative to blood transfusions. Bulletin of Pirogov National Medical & Surgical Center. 2019;14(4):121-122. (In Russ.)